NCI-2024-09084

An Open-Label, Multicenter Study of LY4050784, a Selective SMARCA2/BRM Inhibitor, inAdvanced Solid Tumor Malignancies with SMARCA4/BRG1 Alterations- J5M-OX-JOXA

This is an open label and multicenter research study exploring a new drug, LY4050784, that targets the SMARCA2/BRM proteins. The study is enrolling patients with advanced solid tumors that have specific alterations in the SMARCA4 or BRG1 genes. These are proteins that are part of the SWI/SNF complex, a group of proteins that help regulate gene expression. Mutations in these proteins have been implicated in some cancers. This drug is designed to block the activity of SMARCA2/BRM.

Open label: Patients know which treatments are being given to them

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06561685

Clinical Trial Site: Columbia

To see all available clinical trials click here.